[go: up one dir, main page]

MX2020012914A - Proteina andamio para la generacion de proteinas quimericas de union a antigeno. - Google Patents

Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Info

Publication number
MX2020012914A
MX2020012914A MX2020012914A MX2020012914A MX2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A
Authority
MX
Mexico
Prior art keywords
chimeric proteins
scaffold protein
antigen
generation
binding chimeric
Prior art date
Application number
MX2020012914A
Other languages
English (en)
Inventor
Navarro Alexei Fedorovish Licea
Espinoza Salvador Dueñas
Campos Liliana Noemí Sánchez
Original Assignee
Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese filed Critical Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese
Priority to MX2020012914A priority Critical patent/MX2020012914A/es
Priority to EP21898766.7A priority patent/EP4253399A4/en
Priority to US18/253,971 priority patent/US20230374072A1/en
Priority to PCT/MX2021/050077 priority patent/WO2022114946A1/es
Publication of MX2020012914A publication Critical patent/MX2020012914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C07K16/104—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una proteína de andamio de SEQ ID NO: 1 derivada de una conotoxina, que no presenta residuos de aminoácidos asociados a la actividad tóxica de la conotoxina, y que puede ser usada para la generación de proteínas quiméricas de entre 19 a 47 aminoácidos, insertándole entre sus aminoácidos 11 y 12, fragmentos de un CDR3 de un vNAR con afinidad por un antígeno específico.
MX2020012914A 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno. MX2020012914A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.
EP21898766.7A EP4253399A4 (en) 2020-11-27 2021-11-19 Scaffolding protein for generating antigen-binding chimeral proteins
US18/253,971 US20230374072A1 (en) 2020-11-27 2021-11-19 Scaffolding protein for generating antigen-binding chimeral proteins
PCT/MX2021/050077 WO2022114946A1 (es) 2020-11-27 2021-11-19 Proteína andamio para la generación de proteínas quiméricas de unión a antígeno

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Publications (1)

Publication Number Publication Date
MX2020012914A true MX2020012914A (es) 2022-05-30

Family

ID=81754659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Country Status (4)

Country Link
US (1) US20230374072A1 (es)
EP (1) EP4253399A4 (es)
MX (1) MX2020012914A (es)
WO (1) WO2022114946A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064658A1 (en) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
EP4257599A3 (en) * 2016-01-13 2024-01-17 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region

Also Published As

Publication number Publication date
EP4253399A1 (en) 2023-10-04
US20230374072A1 (en) 2023-11-23
WO2022114946A1 (es) 2022-06-02
EP4253399A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
NZ781143A (en) Anti-vegf protein compositions and methods for producing the same
EA201991099A1 (ru) Антитела против cd73 и их применение
PE20221021A1 (es) Proteinas de union a antigeno que se unen especificamente a mage-a
JP6564777B2 (ja) 多量体ＩｇＡ型遺伝子組換え抗体を含む組成物及びその利用
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
CA2977350A1 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
MX2020007024A (es) Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
PE20230348A1 (es) Variantes de anticuerpos felinos
JP2018518475A (ja) 中和抗インフルエンザ結合分子及びその使用
EA202092458A1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
PE20230840A1 (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
US20250051480A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
PE20210020A1 (es) Anticuerpos injertados con peptido natriuretico auricular
MX381726B (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
MX2022009607A (es) Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia.
KR20210038580A (ko) 새로운 결합 특이성을 항체에 부여하는 초범용법
MX2020006328A (es) Composición inmunogénica.
NZ760789A (en) Uti fusion proteins
EA202193222A1 (ru) Определение характеристик домен-специфических зарядовых вариантов антител
Xin et al. Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties
MX2020012914A (es) Proteina andamio para la generacion de proteinas quimericas de union a antigeno.